0

PD-1 and PD-L1 Inhibitors Market by Application and Geography - Forecast and Analysis 2022-2026

  • Published: Aug 2022
  • Pages: 122
  • SKU: IRTNTR74085
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 49.34 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 19.31%.

This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and Rest of World (ROW)). The programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market report also offers information on several market vendors, including Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd. among others.

What will the PD-1 and PD-L1 Inhibitors Market Size be During the Forecast Period?

pd1 and pdl1 Inhibitors Market Size

Download Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics

 

PD-1 and PD-L1 Inhibitors Market: Key Drivers, Trends, and Challenges

The increasing prevalence of cancer is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the high cost of available PD-1 and PD-L1 inhibitors may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key PD-1 and PD-L1 Inhibitors Market Driver

One of the key factors driving growth in the PD-1 and PD-L1 inhibitors market is the increasing prevalence of cancer. The prevalence of cancer witnessed a significant rise in recent years globally, and the global oncology therapeutics market witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors. The new cases of cancer have increased significantly in recent years owing to factors such as the increasing geriatric population and changes in lifestyle. Various pharmaceutical companies are conducting heavy research on developing novel PD-1 and PD-L1 inhibitors to meet this demand, and the approval of these drugs has risen in recent years. The increasing approvals of these inhibitors for the treatment of various cancer indications are expected to increase their demand, which is expected to lead to the growth of the global PD-1 and PD-L1 inhibitors market.

Key PD-1 and PD-L1 Inhibitors Market Trend

The strong pipeline is a PD-1 and PD-L1 inhibitors market trend that is expected to have a positive impact in the coming years. The global Programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market witnesses the presence of various large pharmaceutical players with novel therapies in the pipeline for the treatment of various types of cancers. The superior efficacy of approved PD-1 and PD-L1 inhibitors has led various companies to conduct research on more advanced therapies to treat various cancer indications. As a result, the demand for these inhibitors is increasing, with highly promising therapies in the late stages of clinical trials. Although certain cancer medicines are still in the early phases of development, vendors benefit from specific drug designations granted by regulatory authorities such as the US FDA and EMA, which assist the drugs in obtaining faster clearance. Such novel drugs are expected to receive marketing clearance for various indications, and the market in focus is expected to witness growth.

Key PD-1 and PD-L1 Inhibitors Market Challenge

The high cost of available PD-1 and PD-L1 inhibitors will be a major challenge for the PD-1 and PD-L1 inhibitors market during the forecast period. The high cost associated with the treatment using PD-1 and PD-L1 inhibitor drugs is the major challenge faced by the global PD-1 and PD-L1 inhibitors market. The high cost of cancer treatment is mainly due to hospitalization, laboratory tests, and the administration of novel PD-1 and PD-L1 inhibitor therapeutics. The treatment cost of PD-1 and PD-L1 inhibitor therapeutics also depends on the stage of cancer. The cost of the PD-1 and PD-L1 inhibitors treatment is very high in developing and underdeveloped countries. This is leading to an increase in the preference for alternative treatment options such as surgeries, which is the most common treatment for solid and blood-related tumors. Therefore, such high treatment costs reduce patient adherence to treatment, thereby hindering the growth of the focused market.

This Programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global PD-1 and PD-L1 inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market during the forecast period.

Who are the Major PD-1 and PD-L1 Inhibitors Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Akeso Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck and Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Shanghai Jhunsi Biosciences Ltd.

 

This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • amgen.com - The company offers PD-1 and PD-L1 inhibitors namely Talimogene Laherparepvec.

  • amgen.com - The unified segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The PD-1 and PD-L1 inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

PD-1 and PD-L1 Inhibitors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the PD-1 and PD-L1 inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for PD-1 and PD-L1 Inhibitors Market?

pd1 and pdl1 Inhibitors Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

51% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The sales of approved therapeutics and the increasing prevalence of various solid tumors and blood-related tumors in the region will facilitate the PD-1 and PD-L1 inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 negatively impacted the market in focus in North America. Owing to the adverse effects of the pandemic, numerous cancer treatment facilities were compelled to lay off employees. Thus, numerous vendors in the market in focus faced shortages in personnel and raw materials that further led to disruptions in the supply chains for the production of PD-1 and PD-L1 inhibitor drugs. However, in the second half of 2020, several market vendors offered PD-1 and PD-L1inhibitor drugs through digital channels, which enabled the market to deal with the negative effects of the pandemic by registering growth through online sales. Furthermore, in 2021, owing to large-scale vaccination drives and the resumption of operations in healthcare units, larger inflows of patients resumed treatment of melanoma in healthcare facilities in North America as compared to 2020 due to the removal of lockdown restrictions. 

What are the Revenue-generating Application Segments in the PD-1 and PD-L1 Inhibitors Market?

pd1 and pdl1 Inhibitors Market Share

To gain further insights on the market contribution of various segments Request PDF Sample

The PD-1 and PD-L1 inhibitors market share growth by the blood-related tumors segment will be significant during the forecast period. The blood-related tumor segment is expected to grow significantly during the forecast period owing to the strong prevalence of leukemia and various types of lymphomas globally.

This report provides an accurate prediction of the contribution of all the segments to the growth of the programmed cell death protein 1 (PD-1) & programmed cell death ligand 1 (PD-L1) inhibitors market size and actionable market insights on post COVID-19 impact on each segment.

 

Programmed Cell Death Protein 1 & Programmed Cell Death Ligand 1 Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 19.31%

Market growth 2022-2026

$ 49.34 billion

Market structure

Fragmented

YoY growth (%)

18.6

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this PD-1 and PD-L1 Inhibitors Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive PD-1 and PD-L1 inhibitors market growth during the next five years
  • Precise estimation of the PD-1 and PD-L1 inhibitors market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the PD-1 and PD-L1 inhibitors industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of programmed cell death protein 1 (PD-1) & programmed cell death ligand 1 (PD-L1) inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Application

    • 5.1 Market segments
      • Exhibit 24: Chart on Application - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Application - Market share 2021-2026 (%)
    • 5.2 Comparison by Application
      • Exhibit 26: Chart on Comparison by Application
      • Exhibit 27: Data Table on Comparison by Application
    • 5.3 Solid tumors - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Solid tumors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Solid tumors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Solid tumors - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Solid tumors - Year-over-year growth 2021-2026 (%)
    • 5.4 Blood-related tumors - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Blood-related tumors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Blood-related tumors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Blood-related tumors - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Blood-related tumors - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Application
      • Exhibit 36: Market opportunity by Application ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 Canada - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 France - Market size and forecast 2021-2026
      • Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Amgen Inc.
              • Exhibit 85: Amgen Inc. - Overview
              • Exhibit 86: Amgen Inc. - Product / Service
              • Exhibit 87: Amgen Inc. - Key offerings
            • 10.4 AstraZeneca Plc
              • Exhibit 88: AstraZeneca Plc - Overview
              • Exhibit 89: AstraZeneca Plc - Product / Service
              • Exhibit 90: AstraZeneca Plc - Key news
              • Exhibit 91: AstraZeneca Plc - Key offerings
            • 10.5 BeiGene Ltd.
              • Exhibit 92: BeiGene Ltd. - Overview
              • Exhibit 93: BeiGene Ltd. - Business segments
              • Exhibit 94: BeiGene Ltd. - Key offerings
              • Exhibit 95: BeiGene Ltd. - Segment focus
            • 10.6 Bristol Myers Squibb Co.
              • Exhibit 96: Bristol Myers Squibb Co. - Overview
              • Exhibit 97: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 98: Bristol Myers Squibb Co. - Key offerings
            • 10.7 Eli Lilly and Co.
              • Exhibit 99: Eli Lilly and Co. - Overview
              • Exhibit 100: Eli Lilly and Co. - Product / Service
              • Exhibit 101: Eli Lilly and Co. - Key offerings
            • 10.8 F. Hoffmann La Roche Ltd.
              • Exhibit 102: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 103: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 104: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 105: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 106: F. Hoffmann La Roche Ltd. - Segment focus
            • 10.9 GlaxoSmithKline Plc
              • Exhibit 107: GlaxoSmithKline Plc - Overview
              • Exhibit 108: GlaxoSmithKline Plc - Business segments
              • Exhibit 109: GlaxoSmithKline Plc - Key news
              • Exhibit 110: GlaxoSmithKline Plc - Key offerings
              • Exhibit 111: GlaxoSmithKline Plc - Segment focus
            • 10.10 Merck and Co. Inc.
              • Exhibit 112: Merck and Co. Inc. - Overview
              • Exhibit 113: Merck and Co. Inc. - Business segments
              • Exhibit 114: Merck and Co. Inc. - Key news
              • Exhibit 115: Merck and Co. Inc. - Key offerings
              • Exhibit 116: Merck and Co. Inc. - Segment focus
            • 10.11 Merck KGaA
              • Exhibit 117: Merck KGaA - Overview
              • Exhibit 118: Merck KGaA - Business segments
              • Exhibit 119: Merck KGaA - Key news
              • Exhibit 120: Merck KGaA - Key offerings
              • Exhibit 121: Merck KGaA - Segment focus
            • 10.12 Sanofi
              • Exhibit 122: Sanofi - Overview
              • Exhibit 123: Sanofi - Business segments
              • Exhibit 124: Sanofi - Key news
              • Exhibit 125: Sanofi - Key offerings
              • Exhibit 126: Sanofi - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 127: Inclusions checklist
                • Exhibit 128: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 129: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 130: Research methodology
                • Exhibit 131: Validation techniques employed for market sizing
                • Exhibit 132: Information sources
              • 11.5 List of abbreviations
                • Exhibit 133: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Pd1 and pdl1 Inhibitors market growth will increase by $49341.12 million during 2022-2026.
              The pd1 and pdl1 inhibitors market is expected to grow at a CAGR of 19.31% during 2022-2026.
              Technavio has segmented the pd1 and pdl1 inhibitors market by geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Shanghai Jhunsi Biosciences Ltd. are a few of the key vendors in the pd1 and pdl1 inhibitors market.
              North America will register the highest growth rate of 50.77% among the other regions. Therefore, the pd1 and pdl1 inhibitors market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the pd1 and pdl1 inhibitors market growth are:
              • Increasing prevalence of cancer
              • Strong pipeline
              The pd1 and pdl1 inhibitors market vendors should focus on grabbing business opportunities from the segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>